Patents by Inventor Zhaodan Cao

Zhaodan Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating glucose metabolism disorders
    Patent number: 8609612
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: December 17, 2013
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
  • Methods of treating glucose metabolism disorders
    Patent number: 8551944
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: October 8, 2013
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan, Peng Zhang
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20130136738
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Application
    Filed: January 21, 2011
    Publication date: May 30, 2013
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20130130975
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Application
    Filed: April 15, 2011
    Publication date: May 23, 2013
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan, Peng Zhang
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20130071391
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Application
    Filed: January 21, 2011
    Publication date: March 21, 2013
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20130017994
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Application
    Filed: February 7, 2011
    Publication date: January 17, 2013
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20120315274
    Abstract: Methods of treating individuals with a glucose metabolism disorder such as diabetes, hyperglycemia, hyperinsulinemia or obesity by administering human FAM3D (family with sequence similarity 3, member D) are provided. Specifically a method of treating hyperglycemia resulting in a reduction of plasma glucose is provided. Additionally, a method of treating hyperinsulinemia resulting in a reduction of plasma glucose is provided. In addition, a method of treating glucose intolerance resulting in an increased glucose tolerance is provided. Pharmaceutical compositions are provided.
    Type: Application
    Filed: January 7, 2011
    Publication date: December 13, 2012
    Inventors: Zhaodan Cao, Yarong Lu, Peng Zhang, Daniel David Kaplan
  • N-aryl pyrazole compounds, compositions, and methods for their use
    Patent number: 8022061
    Abstract: Compounds having formula I: where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: September 20, 2011
    Assignee: Amgen Inc.
    Inventors: Yasuyuki Ogawa, Ryo Okuyama, Satoshi Shibuya, Narihiro Toda, Zhaodan Cao, Zice Fu, Xiaolin Hao, Yong-Jae Kim, Leping Li, Sarah E. Lively, Mike Lizarzaburu, Hui Tian, Ming Yu
  • N-aryl pyrazole compounds, compositions, and methods for their use
    Publication number: 20080153778
    Abstract: Compounds having formula I: where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 26, 2008
    Inventors: Yasuyuki Ogawa, Ryo Okuyama, Satoshi Shibuya, Narihiro Toda, Zhaodan Cao, Zice Fu, Xiaolin Hao, Yong-Jae Kim, Leping Li, Sarah E. Lively, Mike Lizarzaburu, Hui Tian, Ming Yu
  • IKK-?proteins, nucleic acids and methods
    Patent number: 7045613
    Abstract: The invention provides methods and compositions relating to an I?B kinase, IKK-?, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-? encoding nucleic acids or purified from human cells. The invention provides isolated IKK-? hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-? genes, IKK-?-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: May 16, 2006
    Assignee: Amgen, Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IKK-alpha proteins, nucleic acids and methods
    Publication number: 20060019365
    Abstract: The invention provides methods and compositions relating to an I?B kinase, IKK-?, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-? encoding nucleic acids or purified from human cells. The invention provides isolated IKK-? hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-? genes, IKK-?-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Application
    Filed: September 7, 2005
    Publication date: January 26, 2006
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Regnier
  • IRAK3 polynucleotides
    Patent number: 6576444
    Abstract: The invention provides methods and compositions relating to a novel kinase, IRAK3. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IRAK3 encoding nucleic acids or purified from human cells. The invention provides isolated IRAK3 hybridization probes and primers capable of specifically hybridizing with the disclosed IRAK3 genes, IRAK3-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: June 10, 2003
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • IKK-alpha proteins, nucleic acids and methods
    Publication number: 20030077683
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Application
    Filed: September 13, 2002
    Publication date: April 24, 2003
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Regnier
  • IKK-&agr; proteins nucleic acids and methods
    Patent number: 6479266
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: November 12, 2002
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IRAK3 polypeptides, polynucleotides and methods
    Publication number: 20020049300
    Abstract: The invention provides methods and compositions relating to a novel kinase, IRAK3. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IRAK3 encoding nucleic acids or purified from human cells. The invention provides isolated IRAK3 hybridization probes and primers capable of specifically hybridizing with the disclosed IRAK3 genes, IRAK3-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Application
    Filed: May 22, 2001
    Publication date: April 25, 2002
    Inventor: Zhaodan Cao
  • T2k kinase assays
    Patent number: 6365366
    Abstract: T2K kinase activity is detected by forming a mixture of a T2K kinase and a substrate; incubating the mixture under conditions whereby the kinase phosphorylates the substrate at a first rate; and detecting the first rate as an indication of the kinase activity. The substrate comprises SX1X2X3SX4 (SEQ ID NO:1) wherein X1 and X4 are aliphatic residues and both of the S residues are targets of the kinase, and especially, IKK&agr; or IKK&bgr;. In another embodiment, the mixture substrate comprises a particular IL-1 or TNF signaling cascade component. The mixture may be used to screen for agents which modulate the activity of the kinase, e.g. as an immuno-chemiluminescent assay.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: April 2, 2002
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • Interleukin-1 receptor accessory proteins, nucleic acids and methods
    Patent number: 6280955
    Abstract: The invention provides methods and compositions relating to IL-1RAcP proteins that regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IL-1RAcP encoding nucleic acids purified from human cells. The invention provides isolated IL-1RAcP hybridization probes and primers capable of specifically hybridizing with the disclosed IL-1RAcP genes, IL-1RAcP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: August 28, 2001
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • IRAK3 polypeptides and methods
    Patent number: 6262228
    Abstract: The invention provides methods and compositions relating to a novel kinase, IRAK3. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IRAK3 encoding nucleic acids or purified from human cells. The invention provides isolated IRAK3 hybridization probes and primers capable of specifically hybridizing with the disclosed IRAK3 genes, IRAK3-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: July 17, 2001
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235492
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235513
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier